Upcoming event
EAU UROonco: A meeting steered by the EAU Section of Oncological Urology
Back

Tag: EAU22

Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel by stratification factors in the phase 3 ARASENS Trial – Discusssant

How communication between HCPs and (kidney) cancer patients can be improved

State-of-the-art lecture Molecular classification in bladder cancer to guide systemic treatment: ready from prime time?

Overall Survival With Darolutamide Versus Placebo in Combination With Androgen-deprivation Therapy and Docetaxel by Stratification Factors in the Phase 3 ARASENS Trial

State-of-the-art lecture Landscape of current trials with intravesical treatment in high risk BCG naïve NMIBC

State-of-the-art lecture Patient engagement is a potential blockbuster treatment that urologists should prescribe for their cancer patients

[18F]-FDG PET/CT for bladder cancer staging and decision-making in patients with High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC)

Non-muscle invasive bladder cancer subtypes with differential response to intravesical bacillus Calmette-Guerin treatment

Kidney tumours with the 2022, WHO eyes

Effect of robot-assisted radical cystectomy with intracorporeal urinary diversion vs. open radical cystectomy on 90-day morbidity and mortality among patients with bladder cancer: a randomised clinical trial